nder mounting pressure over its pricing for a newly approved for a Duchenne muscular dystrophy drug, Marathon Pharmaceuticals made a surprise move on Thursday and agreed to sell the medicine to PTC Therapeutics, which has been battling US regulators over its own treatment for the disease.

The deal, which will give Marathon $140 million initially and additional milestone payments, comes just one month after Marathon won Food and Drug Administration approval to sell a decades-old steroid and slapped an $89,000 price tag on the drug. PTC, meanwhile, did not say what it will now charge.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy